Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy

J Acquir Immune Defic Syndr. 2003 May 1;33(1):114-6. doi: 10.1097/00126334-200305010-00017.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antiretroviral Therapy, Highly Active
  • Apolipoproteins B / blood*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Cholesterol, VLDL / blood
  • Female
  • HIV Infections / blood*
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / chemically induced
  • Lipids / blood*
  • Male
  • Middle Aged

Substances

  • Apolipoproteins B
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Cholesterol, VLDL
  • HIV Protease Inhibitors
  • Lipids